COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced its plan to finalize a Phase IIb clinical trial protocol with Oxycyte™ for the treatment of traumatic brain injury (TBI) at its Scientific Advisory Board (SAB) meeting scheduled for Thursday, December 13, 2007. Oxycyte is Synthetic Blood’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
